- Home
- JAGX vs VBIO Comparison
JAGX vs VBIO Comparison
Compare JAGX & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAGX | VBIO |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 1.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JAGX | VBIO |
|---|---|---|
| Price | $2.81 | $0.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 62.4K | ★ 132.9K |
| Earning Date | 04-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | N/A |
| Revenue This Year | $61.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.46 |
| 52 Week High | $8.00 | $0.61 |
Technical Indicators
Market Signals| Indicator | JAGX | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 44.72 |
| Support Level | $1.76 | $0.46 |
| Resistance Level | $4.13 | $0.61 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 72.63 | 25.46 |
Price Performance
Historical ComparisonAbout JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.